Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
Author:
Publisher
BMJ
Subject
General Engineering
Cited by 456 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching;Clinical Genitourinary Cancer;2024-12
2. Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials;Clinical and Translational Oncology;2024-09-12
3. Good response to cadonilimab as first-line treatment in superaged patient with advanced gastric cancer: a case report;Immunotherapy;2024-09-11
4. Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapy;Asia-Pacific Journal of Oncology Nursing;2024-09
5. Placebo immune-related adverse events (irAEs): A neglected phenomenon in cancer immunotherapy trials;European Journal of Cancer;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3